Navigation Links
Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
Date:3/10/2010

itability and positive cash flow have allowed the Company to retain the majority of the proceeds for potential new acquisitions.

International Markets

In 2009, the Company announced that it entered into exclusive agreements with Phebra Pty Ltd. for commercialization of Caldolor in Australia and New Zealand, and with DB Pharm Korea for registration and commercialization of the product in South Korea. Phebra and DB Pharm Korea will be responsible for obtaining regulatory approval for Caldolor in their respective territories, and for handling ongoing regulatory requirements, product marketing, distribution and sales. Cumberland will maintain responsibility for product formulation, development and manufacturing, and will provide finished product for sale. Cumberland will receive upfront and milestone payments as well as a transfer price from the partnering companies, and will also receive royalties on any sales of Caldolor in those territories.

New Intellectual Property Initiative for Caldolor


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- CipherHealth, a leading provider of innovations and solutions designed ... to the Nepalese American Nursing Association to donate money ... Nepal to aid in disaster ... addition to helping fund the travel costs for the ... medical supplies for the mission.  "Our ...
(Date:5/5/2015)... 5, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... announced today that it will release its full financial results ... May 11 th before the open, followed by a ... results and business outlook. Participants should call (888) ... (International) and request the InspireMD call. A live webcast of ...
(Date:5/5/2015)... DIEGO, May 5, 2015  Trovagene, Inc. (NASDAQ: ... reported its financial results for the three months ... the first quarter, we presented favorable clinical results ... Cancer Conference, demonstrating our Precision Cancer Monitoring platform,s ... pancreatic, colorectal, and lung cancers," said Antonius Schuh, ...
Breaking Medicine Technology:Five Nurses and Medical Supplies En Route to Nepal With Donation Assistance from CipherHealth 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6
... Aggregate Benefit over Placebo Larger at One Year ... June 11, 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced ... double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer's,disease ... 12 months. Importantly, on every endpoint studied, the ...
... 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced results from ... investigational non-peptide oral platelet growth,factor, PROMACTA(R) (eltrombopag ... at 50-75mg once daily resulted in a,statistically ... bleeding in adult patients with chronic idiopathic,thrombocytopenic ...
Cached Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6
(Date:5/5/2015)... 05, 2015 Horizon Blue Cross Blue ... and secure credit rating of “A” from Standard & ... last week, the Wall Street ratings agency cited the ... position” in determining the rating and “stable” outlook. , ... of our top priorities, so we are pleased to ...
(Date:5/5/2015)... May 05, 2015 Hundreds ... filed on behalf of men who allegedly ... use of prescription testosterone replacement therapies continue ... litigation underway in U.S. District Court, Northern ... dated May 1st, defendants AbbVie, Inc., Auxilium ...
(Date:5/5/2015)... 05, 2015 Sunny skies and cool temperatures ... as nearly 400 runners and walkers participated in Global Lyme ... nearly $35,000. , The 5K and 10K runs and ... disease and to raise funds for tick-borne disease research. The ... the recent merger of Lyme Research Alliance (LRA) ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 In a April ... The Herald-Times , the Missouri State Highway Patrol (MSHP) ... Methamphetamine production or use for the second year in a ... to the FBI, reported 1,469 incidents in 2014 alone, around ... only around 2% of the US Population calls Indiana home, ...
(Date:5/5/2015)... 05, 2015 The brains of people ... that correlate with slower information processing, according to research ... of Public Health . , The findings indicate ... 1 diabetes for cognitive difficulties. If progressive, these changes ... study, funded by the National Institutes of Health ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Maintains “A” Credit Rating from Standard & Poor’s 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 2Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 3Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 2Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 3Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 4
... Washington: A novel study has portrayed the benefits of subjecting ... reduce the regularity// of antibiotic use. This is perhaps the ... rapid influenza testing on adults. The study is published in ... explain the benefits of this diagnostic tool, revealed that 86 ...
... the January 22 issue of Archives of Internal Medicine, one ... appears to increase// the level of the essential mineral in ... in patients with HIV infection. ,Advances in antiretroviral ... however, strict adherence to the therapy is required to keep ...
... A new research by University of Leeds scientists (UK) discovers ... for our bodies to make their own medicine// and there ... ,Professor Simon Carding of Leeds' Faculty of Biological Sciences ... it produce a treatment for Inflammatory Bowel Disease (IBD). Bacteria ...
... assessing the daily activity patterns of thousands of individuals ... the human circadian// clock becomes coupled to so-called local ... work according to a common "social time" that is ... also indicated that city dwellers appear to experience a ...
... more than a dozen people have taken ill and have ... as ‘false’ and ‘ baseless’ by spokesman Xiong Yuanda of ... there was no infectious ‘unknown’ disease, doing the rounds in ... from the Health bureau has sought to dispel reports carried ...
... diarrhoea and gastro-enteritis among infants and children worldwide, and is ... watery// diarrhea in children younger than five years of age. ... of 20 percent and 38 per cent cases in Pakistan ... Kharadar Hospital, respectively. ,The virus is a ...
Cached Medicine News:Health News:Selenium Supplements May Suppress HIV Viral Load 2Health News:A Spoonful Of Sugar to 'Switch' the Bacteria on and Off 2Health News:Chronotype, a Measure to Assess Patterns of Daily Activities 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: